The market value for cell therapies is expected to triple in size by 2025 to $8.21 bn, with investment also having increased by 64% since 2017 to $7.6 bn. Cell therapies have a huge commercial potential however scaled manufacturing, automation, logistics, regulation, and quality control continue to be limiting factors. Before cell therapies can make a mainstream clinical impact, patient access increased and truly reach their commercial potential, these obstructions need to be improved. The Vein-to-Vein Congress will gather manufacturing, operations, site managers and logistical heads from both Biotechs and pharmaceutical companies to address these bottlenecks and facilitate the commercial manufacture of cell therapies. As the cell therapy industry shifts from manual to automated manufacturing, the Vein-to-Vein Congress will discuss the measures that leading companies have put in place to streamline their manufacturing process, scale-up over time and ensure a water-tight supply chain with tracking and trackability from cell collection to patient.